Literature DB >> 14551484

Substantial variability in community respiratory syncytial virus season timing.

James A Mullins1, Ashley C Lamonte, Joseph S Bresee, Larry J Anderson.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is the major cause of bronchiolitis and pneumonia in young children. Prevention of RSV disease in children in certain high risk groups through use of immunoglobulin preparations has been recommended by the American Academy of Pediatrics since 1998. A more precise understanding of the timing of annual RSV epidemics should assist providers in maximizing the benefit of these preventive therapies. The objective of this study was to determine whether current national RSV surveillance data could be used to define the timing of seasonal outbreaks
METHODS: Weekly RSV testing data from the National Respiratory and Enteric Viruses Surveillance System for the period July 1990 through June 2000 were analyzed. RSV season onset week, peak week and duration were calculated for the entire United States, Census regions and select local laboratories. Season variability was estimated by comparing calculations for individual RSV seasons to median measurements for the entire surveillance period
RESULTS: RSV seasons in the South region began significantly earlier (P < 0.05) and lasted longer (P < 0.05) than seasons for the rest of the nation. RSV seasons in the Midwest region began significantly later (P < 0.01) and were shorter (P < 0.05) than those for the rest of the nation. Local RSV seasons varied substantially by year and by laboratory. The variability between laboratories generally increased with distance between laboratories
CONCLUSIONS: Onset weeks and durations of RSV seasons vary substantially by year and location. Local RSV data are needed to accurately define the onset and offset of RSV seasons and to refine timing of passive immune prophylaxis therapy recommendations.

Entities:  

Mesh:

Year:  2003        PMID: 14551484     DOI: 10.1097/01.inf.0000090921.21313.d3

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  55 in total

1.  Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

Authors:  Daniel M Weinberger; Joshua L Warren; Claudia A Steiner; Vivek Charu; Cécile Viboud; Virginia E Pitzer
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

2.  Eighteen Years of Respiratory Syncytial Virus Surveillance: Changes in Seasonality and Hospitalization Rates in Southwestern Alaska Native Children.

Authors:  Dana J T Bruden; Rosalyn Singleton; Carolyn S Hawk; Lisa R Bulkow; Stephen Bentley; Larry J Anderson; Leslie Herrmann; Lori Chikoyak; Thomas W Hennessy
Journal:  Pediatr Infect Dis J       Date:  2015-09       Impact factor: 2.129

3. 

Authors:  Teeranai Sakulchit; Ran D Goldman
Journal:  Can Fam Physician       Date:  2016-12       Impact factor: 3.275

4.  Bronchiolitis outbreak caused by respiratory syncytial virus in southwest Bangladesh, 2010.

Authors:  Farhana Haque; M Mushtuq Husain; Kazi Mohammad Hassan Ameen; Refat Rahima; M Jahangir Hossain; A S M Alamgir; Mustafizur Rahman; Mahmudur Rahman; Stephen P Luby
Journal:  Int J Infect Dis       Date:  2012-08-29       Impact factor: 3.623

Review 5.  Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; D James Nokes; Bradford D Gessner; Mukesh Dherani; Shabir A Madhi; Rosalyn J Singleton; Katherine L O'Brien; Anna Roca; Peter F Wright; Nigel Bruce; Aruna Chandran; Evropi Theodoratou; Agustinus Sutanto; Endang R Sedyaningsih; Mwanajuma Ngama; Patrick K Munywoki; Cissy Kartasasmita; Eric A F Simões; Igor Rudan; Martin W Weber; Harry Campbell
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

6.  Determining the Seasonality of Respiratory Syncytial Virus in the United States: The Impact of Increased Molecular Testing.

Authors:  Claire M Midgley; Amber K Haynes; Jason L Baumgardner; Christina Chommanard; Sara W Demas; Mila M Prill; Glen R Abedi; Aaron T Curns; John T Watson; Susan I Gerber
Journal:  J Infect Dis       Date:  2017-08-01       Impact factor: 5.226

Review 7.  Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma.

Authors:  Shyam S Mohapatra; Sandhya Boyapalle
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

8.  Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.

Authors:  Stuart A Cohen; Robert Zanni; Alan Cohen; Molly Harrington; Paul VanVeldhuisen; Marnie L Boron
Journal:  Pediatr Cardiol       Date:  2007-10-10       Impact factor: 1.655

9.  Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Authors:  Caroline Fenton; Lesley J Scott; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Pharmacological management of acute bronchiolitis.

Authors:  Melvin Wright; Charles J Mullett; Giovanni Piedimonte
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.